BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 17, 2003
View Archived Issues
Interim results for rAAT in otitis media
Read More
GSK researchers describe new Lp-PLA2 inhibitors and their use in atherosclerosis therapy
Read More
Heterocyclic PPAR agonists under study at Novartis
Read More
Schering AG claims new antiandrogen agents for prostate cancer and other uses
Read More
Bayer scientists discover novel alpha7 nAChR agonists with utility in cognition deficits
Read More
Azole compounds for diabetes, cancer and lipoprotein disorders claimed by Maxia
Read More
New series of chemokine CCR3 receptor modulators identified at BMS
Read More
Morphochem presents new tryptase and uPA inhibitors
Read More
Factor Xa inhibitors prepared and tested by Aventis researchers
Read More
Statistically significant imbalance in adverse events in Hemolink trial
Read More
Positive phase I results for EOquin support initiation of phase II testing
Read More
GSK and Pozen to develop and commercialize novel migraine treatment
Read More
Phase III program under way for once-weekly idraparinux
Read More
EMEA expands Zometa labeling
Read More
Dendreon's phase III trial will serve as basis for Provenge approval
Read More
FDA approval for Stalevo
Read More
Positive phase III topline results for Alprox-TD
Read More
Niaspan receives U.K. approval
Read More
Glucose- and triglyceride-lowering effects of a novel pan-PPAR agonist in ZDF rats
Read More
DRF-4832 improves hyperglycemia, hyperlipidemia, hypertension and atherosclerosis in animal models
Read More
Preclinical and clinical efficacy of MK-767, a dual PPARalpha/PPARgamma agonist
Read More
Preclinical activity of LY-519818, a PPARgamma-dominant agonist
Read More
Inhibition of glycogen phosphorylase/hepatic glycogenolysis as an approach to type 2 diabetes
Read More
Spotlight on melatonin
Read More
Long-term efficacy and safety results reported for lanthanum carbonate in chronic renal failure
Read More
Interferon alfa variants with enhanced immunomodulatory and antitumor activity
Read More